Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel process for preparing (+)-cis-sertraline

a technology of cis/trans-sertraline and process, which is applied in the field of new process for preparing (+)cissertraline, can solve the problems of cis/trans-sertraline as described, the cost of multiple recrystallizations, and the complexity of 518 patents

Inactive Publication Date: 2002-02-14
TEVA PHARM USA INC
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0023] The methods of the present invention for making (+)-cis-sertraline allow sertraline-precipitant, or sertraline-mandelate, to be made directly from the sertraline racemate resulting from the hydrogenation, reduction, of the sertraline-1-imine. This improved, efficient and cost effective purification is possible when the sertraline racemate has a relatively high cis / trans ratio, such as, about 8:1 to about 12:1, as well as when the content of dechlorinated-sertraline side products is low, such as, less than about 1%. The methods of the present invention successfully eliminate the need for several purification steps prior to selectively precipitating (+)-cis-sertraline with an optically active selective precipitant.
[0026] The methods of the present invention provide a quick, efficient method for accomplishing the very sensitive process of optical resolution. Table 3 provides additional data and reaction conditions concerning optical resolution. The present improved, efficient and cost effective purification is possible when the sertraline racemate has a relatively high cis / trans ratio, such as, about 8:1 to 12:1. The methods of the present invention successfully eliminate the need for several purification steps prior to selectively precipitating (+)-cis-sertraline with an optically active selective precipitant.

Problems solved by technology

One very problematic group of side products are dechlorinated-sertraline derivatives.
)-cis / trans-sertraline as described in the '518 patent is relatively complicated and expensive requiring multiple recrystallizations, and the (.+-.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel process for preparing (+)-cis-sertraline
  • Novel process for preparing (+)-cis-sertraline
  • Novel process for preparing (+)-cis-sertraline

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0028] Step 1: Preparation of Sertraline-1-imine (Schiff Base):

[0029] Sertralone (100 g) was dissolved in toluene (1400 mL) and the solution so obtained was cooled to 0-5.degree. C. Methyl amine gas (38.7 g) was bubbled through the solution while maintaining the temperature between 0-5.degree. C. To the above solution, TiCl.sub.4 (20 mL) was added dropwise while maintaining the temperature below 10.degree. C. The reaction mixture was allowed to warm to room temperature and then was stirred at room temperature for 3 hours. Upon completion of the reaction, TiO.sub.2 was removed by filtration and the filtrate was evaporated to dryness. The solid obtained after evaporation was sertraline-1-imine (101.17 g; yield 100%).

[0030] Step 2: Preparation of (.+-.)-cis / trans-sertraline (Sertraline Racemate) Free Base:

[0031] A slurry of sertraline-1-imine (Schiff base) (10 g) in t-butyl-methyl-ether (MTBE) (270 mL) was hydrogenated in the presence of Pd / C (10% loading) at 40.degree. C., at 1 atm H....

example 2

Optical Resolution

[0040] (.+-.)-Sertraline hydrochloride (5 g) was dissolved in ethanol (20 mL) and KOH powder (85%) was added to the solution. The slurry was stirred at room temperature for 2.5 hrs. After stirring the solids were removed by filtration and the solution was treated with D-(-)-mandelic acid (2.66 g). Precipitation occurred and the stirring was continued for 24 hours. (+)-Sertraline-mandelate was isolated by filtration and washed with ethanol and then dried to yield 2.70 g of (+)-sertraline-mandelate.

[0041] Optical purity of (+)-sertraline-mandelate was established by chiral HPLC methods. Table 3 provides additional data and reaction conditions concerning the optical resolution of sertraline. In Table 3, the % Enantiomer RR is the percent area of the RR-enantiomer as determined by chiral HPLC; Chiracel OD-H, 250.times.4.6 nm, 5.mu., column temperature 5.degree. C. In Table 3, the Yield % is the yield of optical resolution, based on the % SS-enantiomer of sertraline hyd...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Percent by massaaaaaaaaaa
Login to View More

Abstract

The present invention is directed to (+)-cis-sertraline hydrochloride and methods of preparation. The present invention also includes processes for making sertraline having a cis / trans ratio greater than 3:1, greater than or equal to 8:1, or between about 8:1 and about 12:1, from the Schiff base of sertralone, sertraline-1-imine.

Description

CROSS-REFERENCE TO RELATED INVENTIONS[0001] This application claims the benefit of provisional application Ser. No. 60 / 189,355, filed Mar. 14, 2000; which is incorporated herein by reference.[0002] The present invention relates to the novel process of making and purifying (+)-cis-sertraline.BACKGROUND OF INVENTION[0003] Sertraline hydrochloride, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-t-etrahydro-N-methyl-1-naphthalenamine hydrochloride, having the formula 1[0004] is the active ingredient in Zoloft.RTM., a medication approved by the U.S. Food and Drug Administration, for the treatment of depression, obsessive-compulsive disorder and panic disorder. 2[0005] U.S. Pat. No. 4,536,518 describes a synthesis of sertraline hydrochloride from sertralone. The process for synthesizing sertraline hydrochloride from sertralone comprises two steps. First, sertralone is condensed with methyl amine in the presence of an acid catalyst, to yield the Schiff base of sertralone, sertraline-1-imine. 3[00...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07B57/00C07B61/00C07C209/52C07C209/88C07C211/42
CPCC07B2200/09C07C209/52C07C2102/10C07C211/42C07C2602/10C07B57/00C07C209/88
Inventor MENDELOVICI, MARIOARANIDAM, TAMARPILARSKY, GIDEONGERSHON, NEOMI
Owner TEVA PHARM USA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com